Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Irinotecan hydrochloride by Ipsen for Extrahepatic Bile Duct Cancer: Likelihood of Approval
Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase II for Extrahepatic Bile Duct Cancer. According to...
Irinotecan hydrochloride by Ipsen for Metastatic Biliary Tract Cancer: Likelihood of Approval
Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase II for Metastatic Biliary Tract Cancer. According to...
Elafibranor by Ipsen for Primary Sclerosing Cholangitis: Likelihood of Approval
Elafibranor is under clinical development by Ipsen and currently in Phase II for Primary Sclerosing Cholangitis. According to GlobalData, Phase...
Irinotecan hydrochloride by Ipsen for Solid Tumor: Likelihood of Approval
Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Cabozantinib s-malate by Ipsen for Adrenocortical Carcinoma (Adrenal Cortex Cancer): Likelihood of Approval
Cabozantinib s-malate is under clinical development by Ipsen and currently in Phase II for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According...
Cabozantinib s-malate by Ipsen for Neuroendocrine Cancer: Likelihood of Approval
Cabozantinib s-malate is under clinical development by Ipsen and currently in Phase II for Neuroendocrine Cancer. According to GlobalData, Phase...
Irinotecan hydrochloride by Ipsen for Neuroendocrine Carcinoma: Likelihood of Approval
Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase II for Neuroendocrine Carcinoma. According to GlobalData, Phase...
Irinotecan hydrochloride by Ipsen for Epithelial Ovarian Cancer: Likelihood of Approval
Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData,...
Irinotecan hydrochloride by Ipsen for Rhabdomyosarcoma: Likelihood of Approval
Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase I for Rhabdomyosarcoma. According to GlobalData, Phase I...
Irinotecan hydrochloride by Ipsen for Neuroblastoma: Likelihood of Approval
Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase I for Neuroblastoma. According to GlobalData, Phase I...
Irinotecan hydrochloride by Ipsen for Ewing Sarcoma: Likelihood of Approval
Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase I for Ewing Sarcoma. According to GlobalData, Phase...
Irinotecan hydrochloride by Ipsen for Osteosarcoma: Likelihood of Approval
Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase I for Osteosarcoma. According to GlobalData, Phase I...
IPN-01194 by Ipsen for Solid Tumor: Likelihood of Approval
IPN-01194 is under clinical development by Ipsen and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
IPN-01194 by Ipsen for Metastatic Colorectal Cancer: Likelihood of Approval
IPN-01194 is under clinical development by Ipsen and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
IPN-01194 by Ipsen for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
IPN-01194 is under clinical development by Ipsen and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
IPN-01194 by Ipsen for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
IPN-01194 is under clinical development by Ipsen and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....
IPN-01194 by Ipsen for Metastatic Melanoma: Likelihood of Approval
IPN-01194 is under clinical development by Ipsen and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
IPN-60260 by Ipsen for Cholestasis: Likelihood of Approval
IPN-60260 is under clinical development by Ipsen and currently in Phase I for Cholestasis. According to GlobalData, Phase I drugs...
IPN-60250 by Ipsen for Liver Diseases: Likelihood of Approval
IPN-60250 is under clinical development by Ipsen and currently in Phase I for Liver Diseases. According to GlobalData, Phase I...
IPN-60250 by Ipsen for Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Likelihood of Approval
IPN-60250 is under clinical development by Ipsen and currently in Phase I for Primary Biliary Cholangitis (Primary Biliary Cirrhosis). According...